Neramexane Mesylate

N/A

Report date: 2023/04/21 14:40:02
NME

Base Information

Drug NameNeramexane Mesylate
Drug Alias Name奈拉美生neramexanum甲磺酸奈拉美生neramexanoNeramexane +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscle-type nicotinic acetylcholine receptor antagonistsGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptorMuscle-type nicotinic acetylcholine receptor
Therapy Area/IndicationsNystagmus, CongenitalAlzheimer DiseaseMultiple Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerz Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerz Pharmaceuticals GmbhForest Laboratories Inc
Active IndicationsN/A
Inactive IndicationsNystagmus, CongenitalAlzheimer DiseaseMultiple Sclerosis +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG